Provided by Tiger Fintech (Singapore) Pte. Ltd.

HBM HOLDINGS-B

15.690
+1.1708.06%
Volume:10.69M
Turnover:166.38M
Market Cap:13.68B
PE:557.59
High:15.850
Open:14.500
Low:14.500
Close:14.520
52wk High:17.980
52wk Low:1.120
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:1.52
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.028
ROE:36.59%
ROA:13.49%
PB:6.22
PE(LYR):557.59
PS:15.19

Loading ...

Hbm Holdings Ltd - Windward Bio Plans Global Copd Trials in 2026

THOMSON REUTERS
·
Jul 23

Hbm Holdings Ltd - Phase 2 Trial Data for Hbm9378/Win378 Expected Mid-2026

THOMSON REUTERS
·
Jul 23

Hbm9378/Win378, a Long-Acting, Fully Human Anti-Tslp Antibody, Enters Global Phase 2 Polaris Trial for Asthma

THOMSON REUTERS
·
Jul 23

HBM Holdings Ltd. Files Disclosure with HKEX Announcing Repurchase of 300,000 Shares at HKD 7.7601 Each

Reuters
·
Jul 11

HBM Holdings Subsidiary, HBM Shanghai, Backs NK Cell-Tech's A+++ Financing Round

Reuters
·
Jul 09

HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX, Announcing Repurchase of 2.3 Million Shares at HKD 818,300

Reuters
·
Jul 07

HBM Holdings Ltd. Announces New Share Option Grant Plan for Employees

Reuters
·
Jul 02

HBM Holdings Ltd. Files Next Day Disclosure to HKEX Announcing Repurchase of 300,000 Shares at HKD 8.1738 Each

Reuters
·
Jun 27

HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX, Announces Repurchase of 1,900,000 Shares at HKD 8.6822 Each

Reuters
·
Jun 25

BRIEF-HBM Holdings Says Strategic Collaboration With Otsuka For HBM7020

Reuters
·
Jun 23

HBM Holdings Ltd. Enters Global Strategic Partnership with Otsuka Pharmaceutical for HBM7020 Development

Reuters
·
Jun 23

HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX, Announces Repurchase of 200,000 Shares at HKD 7.7777 Each

Reuters
·
Jun 19

HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX Announcing Repurchase of 1,100,000 Shares at HKD 7.8443 Each

Reuters
·
Jun 17

BRIEF-HBM Holdings Says China National Intellectual Property Administration Issued Final Decision

Reuters
·
Jun 16

HBM Holdings Ltd. Successfully Defends Patent on Human Heavy Chain-Only Antibodies in China

Reuters
·
Jun 16

HBM Unit to License Antibody Technology to Visterra for Autoimmune Disease Treatments

MT Newswires Live
·
Jun 13

HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX, Announces Repurchase of 500,000 Shares at HKD 4,336,060 Total

Reuters
·
Jun 13

BRIEF-HBM's Unit Enters Into License Agreement With Visterra

Reuters
·
Jun 12

Nona Biosciences, HBM Holdings Subsidiary, Enters License Agreement with Visterra for Biotherapeutic Advancement

Reuters
·
Jun 12

HBM Holdings Ltd. Conducted Annual General Meeting

Reuters
·
Jun 11